Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Emory University |
---|---|
Information provided by: | Emory University |
ClinicalTrials.gov Identifier: | NCT00663143 |
Thiazolidinediones (TZDs) are a commonly used antidiabetic drugs currently used by over a million patients in the United States. Recent studies have shown that treatment with TZD may increase the risk of bone fractures. The cause of bone loss is not known. We believe that TZD may cause increased accumulation of fat in the bone marrow, which may cause decrease bone formation and weak bones. This study aims to determine if TZDs increase the amount of fat and decrease the number of bone producing cells in the bone marrow.
A total of 5 subjects who require surgery for mandible (jaw) fracture and bone graft will be recruited. Some patients who will undergo mandible surgery will require a bone graft. In this procedure, a small piece of bone from the hip is placed in the mandible. In this study, a small amount of bone marrow fluid (5 mL or 1 teaspoon) will be obtained after the bone graft is completed. Obtaining the bone marrow will not result in additional pain or health problems. The effect of TZD on bone marrow and bone forming cells will be studied. The cells obtained during surgery will be grown at Dr Beck's laboratory at Emory University School of Medicine. A working hypothesis suggests that the increased fracture risk in patients taking TZDs is the result of TZDs altering the differentiation capacity of bone marrow stromal cells pushing them towards the adipocyte lineage at the cost of osteoblast formation thereby decreasing bone formation.
Study AIM:To determine whether TZD exposure in vitro alters bone formation and the differentiation capacity of bone marrow stromal cells by promoting adipocyte lineage differentiation and lowering osteoblast formation.
Condition | Intervention |
---|---|
Osteoporosis |
Procedure: Stromal Cells Sample |
Study Type: | Interventional |
Study Design: | Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Thiazolidinedione-Induced Bone Loss: Effects on Bone Marrow Stromal Cell Differentiation Capacity and Osteoblast Formation |
Estimated Enrollment: | 5 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Guillermo Umpierrez, MD | 404.778.1665 | geumpie@emory.edu |
Contact: Dawn Smiley, MD | 404.778.1664 | dsmiley@emory.edu |
United States, Georgia | |
Grady Memorial Hospital | Not yet recruiting |
Atlanta, Georgia, United States, 30303 | |
Contact: Guillermo Umpierrez, MD 404-778-1665 geumpie@emory.edu | |
Contact: Dawn Smiley, MD 4047781664 dsmiley@emory.edu | |
Principal Investigator: Guillermo Umpierrez, MD | |
Emory Crawford Long Hospital | Recruiting |
Atlanta, Georgia, United States, 30308 | |
Contact: Gary Boloux, MD 404-778-4500 gbouloux@hotmail.com | |
Contact: Guillermo Umpierrez, MD 404-778-1665 geumpie@emory.edu | |
Emory University Hospital | Recruiting |
Atlanta, Georgia, United States, 30322 | |
Contact: Gary Bouloux, MD/DDS 404-778-4500 gbouloux@hotmail.com | |
Contact: Guillermo Umpierrez, MD 404-778-1665 geumpie@emory.edu |
Principal Investigator: | Guillermo Umpierrez, MD | Emory University SOM |
Responsible Party: | Emory University School of Medicine ( Guillermo Umpierrez, MD ) |
Study ID Numbers: | e6692, IRB#e6692 |
Study First Received: | April 18, 2008 |
Last Updated: | February 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00663143 History of Changes |
Health Authority: | United States: Institutional Review Board |
investigate if TZD exposure in vitro alters bone |
formation differentiation capacity bone marrow stromal cells |
Hypoglycemic Agents Musculoskeletal Diseases 2,4-thiazolidinedione |
Osteoporosis Bone Diseases, Metabolic Bone Diseases |
Hypoglycemic Agents Musculoskeletal Diseases Physiological Effects of Drugs 2,4-thiazolidinedione |
Osteoporosis Bone Diseases, Metabolic Bone Diseases Pharmacologic Actions |